Is high serum concentration of YKL-40 associated with short survival in patients with acute myeloid leukemia?
Serum YKL-40 is a prognostic biomarker of survival in AML patients. Its role in AML and infections needs to be determined.
High AT(1)R density on blood platelets (a presumable marker of cardiovascular AT(1)R density) drawn in the acute phase of MI predicts poorer left ventricular systolic function in 6-month follow up. This suggests that modern therapy offers suboptimal blockade of renin-angiotensin system activity in the setting of MI.